Gout Therapeutics Market Set to Exceed $6,304.8 Million By 2026 | CAGR 14.8%
Forecast to 2020
Gout Therapeutics Market Size Worth $6,304.8 Million By 2026
“Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents) Disease Condition (Acute, Chronic); By Regions, Segments & Forecast, 2020 - 2026” The global gout therapeutics market size is expected to reach USD 6,304.8 million by 2026 according to a new study by Polaris Market Research. The incidence and prevalence of gout has increased over two-fold in past 20 years. This growth combined with increasing occurrence of comorbid conditions and cardiovascular risk factors represents a significant public health challenge. Globally, the developed countries tend to have a higher burden of gout compared to the developing countries, and also have increasing prevalence of this disease. There are various factors including genetic history, and ethnicity that could lead to occurrence of gout. Also, socioeconomic and dietary factors, as well as comorbidities and medications that can influence uric acid levels and facilitate MSU crystal formation, are also important in determining the risk of developing clinically evident gout. Increasing geriatric population, and growing prevalence of this condition associated with this growing elderly population are the primary factors driving the growth of the industry. According to a study published in the Modern Medicine, elder population are more prone to develop tophi and the prevalence of metabolic syndrome among the elder population with gout was 62%. Currently, the geriatric population is growing at an extraordinary rate. According to the data published by the United Nations in 2012, global geriatric population was nearly 809.4 million in 2011 and is anticipated to grow more than double and reach over 2,000 million by 2050. Browse Detailed Research Report On Gout Therapeutics Market Analysis: https://www.polarismarketresearch.com/industry-analysis/gout-therapeutics-market Furthermore, growing prevalence of this condition across the globe, increasing research and development activities, growing number of product approvals, and increasing public and private investments are some other factors driving the growth of the market during the forecast period. Recently, in New Zealand, the HRC funded Professor Lisa Stamp at the University of Otago to lead the first-ever randomized controlled trial demonstrating an improved dosing strategy using allopurinol to help more patients to manage their gout symptoms. Also, in 2019 researchers at Washington State University Health Sciences Spokane and elsewhere identified a new therapeutic target for the treatment of gout. Such growing research studies are fueling the growth of the market during the forecast period.
-2-
Gout Therapeutics Market Size Worth $6,304.8 Million By 2026
However, factors such as patent expiry of blockbuster products, increasing competition in the generic sector and high cost of the newly launched drugs are likely to hinder the growth of this market during the forecast period. The cost associated with gout therapies is poised to increase dramatically due to federal policy decisions and pipeline developments. Also, patent expiry of major blockbuster agents and expected launch of generic version are likely to restrain the growth of the market during the forecast period. Entry of generic after its patent expiry would decline the revenue in future. Hence, high cost of the products and patent expiry of the medicines is a key factor to restrain the growth of the market. Request
for
sample:
https://www.polarismarketresearch.com/industry-analysis/gout-
therapeutics-market/request-for-sample The global market is dominated by North America as the countries such as US and Canada have a large patient base, and also significant number of research activities are being conducted in this region. Many companies operating in this market segment are based in the US, and hence new products are primarily introduced in this regional segment. Gout affects around 8.3 million people in the United States, with prevalence in range of the 1–4%. The prevalence of gout is higher in African Americans as compared to Caucasians, and is projected to be increasing across all demographics in coming few years. Furthermore, government is also taking various measures to generated awareness and provide better healthcare facilities to the patient suffering with gout in this region. Furthermore, Europe also has a significant share in the global industry. Various international companies have been launching new products in the European market. For instance, in August 2018, Grünenthal received European approval for Duzallo (lesinurad/allopurinol) and extended its gout portfolio. However, Asia-Pacific is projected to witness a fastest growth during the forecast period. This highest growth is mainly anticipated due to the presence of several high economically growing countries such as India, China, South Korea, and other South Asian countries. Increasing number of people linked with smoking and alcohol consumption, growing population, increasing need for effective therapies, and growing expansion of local and international players in this regional segment are also fueling the growth of gout therapeutics market in this region. The key players in the industry include AstraZeneca, Horizon Pharma Plc, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Teijin Pharma Limited, Regeneron Pharmaceuticals, Inc, Ironwood Pharmaceuticals, Inc., JW Pharmaceutical, Selecta Biosciences, Inc., and Grunenthal Group among others.
-3-
Gout Therapeutics Market Size Worth $6,304.8 Million By 2026
1. TABLE OF CONTENTS 2. Chapter 1. Introduction 2.1. Report Description 2.1.1. Objectives of the Study 2.1.2. Market Scope 2.1.3. Assumptions 2.2. Stakeholders 3. Chapter 2. Executive Summary 3.1. Market Highlights 4. Chapter 3. Research Methodology 4.1. Overview 4.1.1. Data Mining 4.2. Data Sources 4.2.1. Primary Sources 4.2.2. Secondary Sources 5. Chapter 4. Market Analysis 5.1. Overview 5.2. Gout Therapeutics Market Dynamics 5.2.1. Drivers and Opportunities 5.2.1.1. Growing Geriatric Population 5.2.1.2. Increasing incidence and prevalence of gout 5.2.1.3. Growing research and development activities 5.2.2. Restraints and Challenges 5.2.2.1. High cost of new and improved drugs 5.2.2.2. Patent expiry of various blockbuster drugs 5.3. Porter’s Five Forces Analysis 5.3.1. Bargaining Power of Suppliers (Moderate) 5.3.2. Threats Of New Entrants: (High) 5.3.3. Bargaining Power Of Buyers (High) 5.3.4. Threats Of Substitute (Moderate) 5.3.5. Rivalry Among The Existing Competitors (Moderate) 5.4. PESTLE Analysis 5.5. Gout Therapeutics Market Industry trends 5.5.1. Newer treatments for gout 5.6. Competitive Ranking Analysis 6. Chapter 5. Gout Therapeutics Market Assessment by Drug Class 6.1. KEY FINDINGS 6.2. Introduction 6.2.1. Global Gout Therapeutics Market, By Type, 2015 – 2026 (USD Million) 6.3. Non-steroidal Anti-Inflammatory Drugs (NSAIDs) 6.3.1. Global Gout Therapeutics NSAIDs Market, by Region, 2015-2026 (USD Million) 6.3.2. North America: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million) 6.3.3. Europe: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million) 6.3.4. Asia-Pacific: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million) 6.3.5. LATAM: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million) 6.3.6. MEA: Gout Therapeutics NSAIDs Market, by Country, 2015-2026 (USD Million) 6.4. Corticosteroids
-4-
Gout Therapeutics Market Size Worth $6,304.8 Million By 2026
6.4.1. Global Gout Therapeutics Corticosteroids Market, by Region, 2015-2026 (USD Million) 6.4.2. North America: Gout Therapeutics Corticosteroids Market, by Country, 20152026 (USD Million) 6.4.3. Europe: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million) 6.4.4. Asia-Pacific: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million) 6.4.5. LATAM: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million) 6.4.6. MEA: Gout Therapeutics Corticosteroids Market, by Country, 2015-2026 (USD Million) 6.5. Colchicine 6.5.1. Global Gout Therapeutics Colchicine Market, by Region, 2015-2026 (USD Million) 6.5.2. North America: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million) 6.5.3. Europe: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million) 6.5.4. Asia-Pacific: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million) 6.5.5. LATAM: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million) 6.5.6. MEA: Gout Therapeutics Colchicine Market, by Country, 2015-2026 (USD Million) 6.6. Urate Lowering Agents 6.6.1. Global Gout Therapeutics Urate Lowering Agents Market, by Region, 2015-2026 (USD Million) 6.6.2. North America: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million) 6.6.3. Europe: Gout Therapeutics Urate Lowering Agents Market, by Country, 20152026 (USD Million) 6.6.4. Asia-Pacific: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million) 6.6.5. LATAM: Gout Therapeutics Urate Lowering Agents Market, by Country, 20152026 (USD Million) 6.6.6. MEA: Gout Therapeutics Urate Lowering Agents Market, by Country, 2015-2026 (USD Million) 7. Chapter 6. Gout Therapeutics Market Assessment by Disease Condition 7.1. KEY FINDINGS 7.2. Introduction 7.2.1. Global Gout Therapeutics Market, By Disease Condition, 2015 – 2026 (USD Million) 7.3. Acute Gout 7.3.1. Global Acute Gout Therapeutics Market, by Region, 2015-2026 (USD Million) 7.3.2. North America: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million) 7.3.3. Europe: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million) 7.3.4. Asia-Pacific: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million) 7.3.5. LATAM: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million) 7.3.6. MEA: Acute Gout Therapeutics Market, by Country, 2015-2026 (USD Million) 7.4. Chronic -5-
Gout Therapeutics Market Size Worth $6,304.8 Million By 2026
7.4.1. Global Chronic Gout Therapeutics Market, by Region, 2015-2026 (USD Million) 7.4.2. North America: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million) 7.4.3. Europe: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million) 7.4.4. Asia-Pacific: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million) 7.4.5. LATAM: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million) 7.4.6. MEA: Chronic Gout Therapeutics Market, by Country, 2015-2026 (USD Million) 8. Chapter 7. Gout Therapeutics Market Assessment by Geography 8.1. KEY FINDINGS 8.2. Introduction 8.2.1. Gout Therapeutics Market Assessment, By Geography, 2015-2026 (USD Million) 8.3. NORTH AMERICA 8.3.1. North America: Gout Therapeutics Market, by Country, 2015-2026 (USD Million) 8.3.2. North America: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.3.3. North America: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.3.4. U.S. 8.3.4.1. U.S.: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.3.4.2. U.S.: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.3.5. Canada 8.3.5.1. Canada: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.3.5.2. Canada: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.4. EUROPE 8.4.1. Europe: Gout Therapeutics Market, by Country, 2015-2026 (USD Million) 8.4.2. Europe: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.4.3. Europe: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.4.4. Germany 8.4.4.1. Germany: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.4.4.2. Germany: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.4.5. UK 8.4.5.1. UK: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.4.5.2. UK: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.4.6. France 8.4.6.1. France: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.4.6.2. France: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.4.7. Italy 8.4.7.1. Italy: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.4.7.2. Italy: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.4.8. Spain
-6-
Gout Therapeutics Market Size Worth $6,304.8 Million By 2026
8.4.8.1. Spain: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.4.8.2. Spain: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.4.9. Belgium 8.4.9.1. Belgium: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.4.9.2. Belgium: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.4.10. Rest of Europe 8.4.10.1. Rest of Europe: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.4.10.2. Rest of Europe: Gout Therapeutics Market, By Disease Condition, 20152026 (USD Million) 8.5. ASIA-PACIFIC 8.5.1. Asia Pacific: Gout Therapeutics Market, by Country, 2015-2026 (USD Million) 8.5.2. Asia Pacific: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.5.3. Asia Pacific: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.5.4. China 8.5.4.1. China: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.5.4.2. China: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.5.5. India 8.5.5.1. India: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.5.5.2. India: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.5.6. Japan 8.5.6.1. Japan: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.5.6.2. Japan: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.5.7. South Korea 8.5.7.1. South Korea: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.5.7.2. South Korea: Gout Therapeutics Market, By Disease Condition, 20152026 (USD Million) 8.5.8. Australia 8.5.8.1. Australia: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.5.8.2. Australia: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.5.9. Rest of APAC 8.5.9.1. Rest of APAC: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.5.9.2. Rest of APAC: Gout Therapeutics Market, By Disease Condition, 20152026 (USD Million) 8.6. LATIN AMERICA 8.6.1. Latin America: Gout Therapeutics Market, by Country, 2015-2026 (USD Million) 8.6.2. Latin America: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) -7-
Gout Therapeutics Market Size Worth $6,304.8 Million By 2026
8.6.3. Latin America: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.6.4. Brazil 8.6.4.1. Brazil: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.6.4.2. Brazil: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.6.5. Mexico 8.6.5.1. Mexico: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.6.5.2. Mexico: Gout Therapeutics Market, By Disease Condition, 2015-2026 (USD Million) 8.6.6. Rest of LATAM 8.6.6.1. Rest of LATAM: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.6.6.2. Rest of LATAM: Gout Therapeutics Market, By Disease Condition, 20152026 (USD Million) 8.7. MIDDLE EAST AND AFRICA 8.7.1. Middle East & Africa: Gout Therapeutics Market, by Country, 2015-2026 (USD Million) 8.7.2. Middle East & Africa: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.7.3. Middle East & Africa: Gout Therapeutics Market, By Disease Condition, 20152026 (USD Million) 8.7.4. South Africa 8.7.4.1. South Africa: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.7.4.2. South Africa: Gout Therapeutics Market, By Disease Condition, 20152026 (USD Million) 8.7.5. Saudi Arabia 8.7.5.1. Saudi Arabia: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.7.5.2. Saudi Arabia: Gout Therapeutics Market, By Disease Condition, 20152026 (USD Million) 8.7.6. Rest of Middle East and Africa 8.7.6.1. Rest of MEA: Gout Therapeutics Market, By Drug Class, 2015-2026 (USD Million) 8.7.6.2. Rest of MEA: Gout Therapeutics Market, By Disease Condition, 20152026 (USD Million) 9. Chapter 8. Competitive Landscape 9.1. Agreements, Collaborations, Product Developments and launch Analysis 9.1.1. Strategic Analysis – Gout Therapeutics Market 9.2. Prouct/Service Launch 9.3. Partnerships/Collaborations/Agreements 9.4. Approvals 9.5. Others 10. Chapter 9. Company Profiles 10.1. AstraZeneca 10.1.1. Business Overview 10.1.2. Financial Snapshot 10.1.3. Products and Services 10.1.4. Recent Developments -8-
Gout Therapeutics Market Size Worth $6,304.8 Million By 2026
10.2. Horizon Pharma Plc 10.2.1. Business Overview 10.2.2. Financial Snapshot 10.2.3. Products and Services 10.2.4. Recent Developments 10.3. Takeda Pharmaceutical Company Limited 10.3.1. Business Overview 10.3.2. Financial Snapshot 10.3.3. Products and Services 10.3.4. Recent Developments 10.4. GlaxoSmithKline plc 10.4.1. Business Overview 10.4.2. Financial Snapshot 10.4.3. Products and Services 10.4.4. Recent Developments 10.5. Novartis AG 10.5.1. Business Overview 10.5.2. Financial Snapshot 10.5.3. Products and Services 10.5.4. Recent Developments 10.6. Merck & Co. Inc. 10.6.1. Business Overview 10.6.2. Financial Snapshot 10.6.3. Products and Services 10.6.4. Recent Developments 10.7. Teijin Pharma Limited 10.7.1. Business Overview 10.7.2. Financial Snapshot 10.7.3. Products and Services 10.7.4. Recent Developments 10.8. Regeneron Pharmaceuticals, Inc. 10.8.1. Business Overview 10.8.2. Financial Snapshot 10.8.3. Products and Services 10.8.4. Recent Developments 10.9. Ironwood Pharmaceuticals, Inc. 10.9.1. Business Overview 10.9.2. Financial Snapshot 10.9.3. Products and Services 10.9.4. Recent Developments 10.10. JW Pharmaceutical 10.10.1. Business Overview 10.10.2. Financial Snapshot 10.10.3. Products and Services 10.10.4. Recent Developments 10.11. Selecta Biosciences, Inc. 10.11.1. Business Overview 10.11.2. Financial Snapshot 10.11.3. Products and Services 10.11.4. Recent Developments 10.12. Grunenthal Group 10.12.1. Business Overview -9-
Gout Therapeutics Market Size Worth $6,304.8 Million By 2026
10.12.2. 10.12.3. 10.12.4.
Financial Snapshot Products and Services Recent Developments
Access Press Release on Gout Therapeutics Market: https://www.polarismarketresearch.com/press-releases/global-gout-therapeutics-market
About Polaris Market Research Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers. E mail Id:
[email protected] Web: www.polarismarketresearch.com Official Blog: http://polarismarketresearch.blogspot.com/
- 10 -